Profound MedicalPROF -2.11%73 Debt-to-Equity is 0.13 as of Mar. 2026, which is 19% below its 10-year median of 0.16. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 705 Medical Devices & Instruments companies, Profound Medical ranks better than 63.4% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Profound Medical's Debt-to-Equity or its related term are showing as below:
PROF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.16 Max: 2.18
Current: 0.13
During the past 12 years, the highest Debt-to-Equity Ratio of Profound Medical was 2.18. The lowest was 0.02. And the median was 0.16.
PROF's Debt-to-Equity is ranked better than 63.4% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs PROF: 0.13
Profound Medical (NAS:PROF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Profound Medical Debt-to-Equity Related Terms
Profound Medical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Profound Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Profound Medical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a Debt-to-Equity of 0.13 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Profound Medical and its competitors. This is 19% below median its historical median of 0.16. Over the past decade, Profound Medical's Debt-to-Equity has ranged from 0.02 to 2.18. According to the industry distribution chart, Profound Medical ranks #258 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 36.6%.
Is Profound Medical's Debt-to-Equity too high?
Profound Medical's current Debt-to-Equity of 0.13 is 19% below median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.18. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Profound Medical's value of 0.13 is 43.5% below this industry median. Based on the distribution chart, Profound Medical ranks #258 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #258 out of 705 companies for Debt-to-Equity. This puts Profound Medical in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Profound Medical's value of 0.13 is 43.5% below this benchmark. Historically, Profound Medical's own Debt-to-Equity has ranged from 0.02 to 2.18 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 0.23, Profound Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Debt-to-Equity of 0.13 is 43.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Debt-to-Equity is 0.13, which is 19% below median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.18 — trading 49.7% below its estimated fair value. The current Debt-to-Equity is 0.13, which is 19% below median its 10-year median of 0.16 and 43.5% below the Medical Devices & Instruments industry median of 0.23. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Profound Medical (PROF), the current Debt-to-Equity is 0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.18 is trading 49.7% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Debt-to-Equity: 0.13 (19% below median its 10-year median of 0.16)
GF Value™: $14.28 vs. price of $7.18 (49.7% below fair value)
Industry Position: 43.5% below the Medical Devices & Instruments median (#258 of 705)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
